ETD002 is a novel TMEM16A chloride channel potentiator Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 17 August 2020: Enterprise Therapeutics
Novel immuno-therapies to overcome the resistance of existing cancer treatments Builds on the world-leading research into tumour associated macrophages (TAMs) Robert Haigh joins as CEO
New UK fund cornerstoned by £50 million investment from the British Business Bank, through its Enterprise Capital Funds (ECF) programme Epidarex Capital III UK LP
Combines Best-in-Class Bone Repair with Intraoperative Ease-of-Use for Spine and Trauma Bone Grafting Applications Aberdeen, UK, 17 June 2020 – SIRAKOSS Ltd, a developer of
71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs.
Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital,
Submission of New Drug Application (NDA) planned for second half of 2020 following successful pre-NDA meeting with FDA WALTHAM, Mass., May 21, 2020 –
No cases of inflammation observed after 12 months with Phase 3 formulation of pegcetacoplan in patients with advanced geographic atrophy (GA) Decrease in mean lesion
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Results support, for the first time, the safety and potential efficacy of an
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer London,